Literature DB >> 18282173

Biologic treatments for systemic rheumatic diseases.

Y Shirota1, G G Illei, N P Nikolov.   

Abstract

Many rheumatologic disorders, most notably Sjögren's syndrome, are associated with dental complications and in some cases oral diseases may trigger or drive connective tissue disease. During the past three decades the treatment in rheumatology was revolutionized by the introduction of disease-modifying anti-rheumatic drugs. Advances in our understanding of the pathogenesis of rheumatic diseases have led to the discovery of critical mechanisms of inflammation and autoimmunity and the invention of new target-specific biologic agents. In this review, we will summarize the current state of biologic therapies in rheumatology and discuss the implications of these on oral health and disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18282173      PMCID: PMC2766248          DOI: 10.1111/j.1601-0825.2008.01440.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  130 in total

1.  T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice.

Authors:  J Törnwall; T E Lane; R I Fox; H S Fox
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

2.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.

Authors:  Frédéric Lavie; Corinne Miceli-Richard; Jeanine Quillard; Sophie Roux; Philippe Leclerc; Xavier Mariette
Journal:  J Pathol       Date:  2004-04       Impact factor: 7.996

4.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

5.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

6.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

7.  Cytokine production, serum levels and disease activity in systemic lupus erythematosus.

Authors:  G Gröndal; I Gunnarsson; J Rönnelid; S Rogberg; L Klareskog; I Lundberg
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

8.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Authors:  Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2004-05

9.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Authors:  Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker
Journal:  Arthritis Rheum       Date:  2004-05

10.  Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.

Authors:  R Horai; S Saijo; H Tanioka; S Nakae; K Sudo; A Okahara; T Ikuse; M Asano; Y Iwakura
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  5 in total

Review 1.  Gene-expression profiling in rheumatic disease: tools and therapeutic potential.

Authors:  Jason W Bauer; Hatice Bilgic; Emily C Baechler
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

2.  Juvenile idiopathic arthritis: management and therapeutic options.

Authors:  Natasha M Ruth; Murray H Passo
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 3.  IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.

Authors:  Hao Li; George C Tsokos
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-13       Impact factor: 8.667

Review 4.  Biologics in children's autoimmune disorders: efficacy and safety.

Authors:  Luciana Breda; Marianna Del Torto; Sara De Sanctis; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

5.  Type I interferon receptor deficiency prevents murine Sjogren's syndrome.

Authors:  B M Szczerba; P D Rybakowska; P Dey; K M Payerhin; A B Peck; H Bagavant; U S Deshmukh
Journal:  J Dent Res       Date:  2013-03-26       Impact factor: 6.116

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.